# Novel Drug Approvals at FDA

## Novel Drug Approvals for 2023

24. **Ojjaara**: Approved on September 15, 2023, Ojjaara, containing momelotinib, is used for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.

25. **Aphexda**: On September 8, 2023, Aphexda, with the active ingredient motixafortide, was approved for use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

26. **Rivfloza**: Rivfloza, containing nedosiran, was approved on September 29, 2023, to lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function.

27. **Paxlovid**: Approved on May 25, 2023, Paxlovid, with the active ingredients nirmatrelvir and ritonavir, is used for the treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19.

28. **Ogsiveo**: On November 27, 2023, Ogsiveo, with the active ingredient nirogacestat, was approved for the treatment of adults with progressing desmoid tumors who require systemic treatment.

29. **Beyfortus**: Approved on July 17, 2023, Beyfortus, containing nirsevimab-alip, is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease.

30. **Skyclarys**: Skyclarys, with the active ingredient omaveloxolone, was approved on February 28, 2023, for the treatment of Friedrichâ€™s ataxias.
